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ABSTRACT 
 
 
Background and Aim  
IL28B polymorphism (IL28Bp) is associated with spontaneous and treatment induced 
HCV clearance, whereas its role in HBV infection is still debated. We analysed the 
correlation between IL28Bp and phase and outcome of HBV infection and HBsAg 
clearance in Interferon (IFN) treated patients.  
Patients and Methods. We studied 525 consecutive chronic HBV carriers (63.4% 
males; median age 47.3 y., range:16-86, genotype D 88%) followed up at the Hepatology 
Unit of the University Hospital of Pisa since 1998. They were 71 HBeAg pos and 454 
HBeAg neg. During follow-up (fu) 138 patients were treated with IFN +/- nucleos(t)ide 
analogues (NA). IL28Bp SNP rs12979860 was characterized by allele-specific RT-PCR 
(LightMix, Roche). Quantitative HBsAg (Architect, Abbott) and HBV-DNA (Cobas 
TaqMan, Roche) were tested at baseline (BL) in all carriers, during therapy (week 1-4-
12-24-48) in 42 Peg-IFN treated pts.  
Results. In the overall population IL28Bp was:  CC 49.7%, CT 40.4% and TT 9.9%. The 
CC allele prevalence was not statistically different according to age, gender (males: 
49.5%), HBeAg status (pos: 59.2%), HBeAg negative inactive (48.2%) or active (49.7%) 
infection. Median Log HBV-DNA and HBsAg levels at BL in CC (4.46 and 3.34), CT (4.40 
and 3.18) and TT (4.34 and 3.19) carriers were comparable. During fu 14/122 (11.5%) 
inactive carriers cleared HBsAg: 7.4% CC,14.8% CT, 14.3% TT, n.s. Among IFN+/- NA 
treated pts, 8/29 (27.6%) HBeAg pos (50% CC) and 21/127 (16.5%) HBeAg neg (33.3% 
CC) lost HBsAg. At multivariate analysis the only independent factor associated with 
HBsAg loss was genotype non D (P=0.009). During peg-IFN mono-therapy week 12 
HBV-DNA, but not HBsAg, became significantly lower in CC (7) than in CT/TT (7/1) 
HBeAg pos pts  (4.94 vs 7.90, P=0.029). No difference was found in HBeAg negative 
pts. 
Conclusions. The IL28B CC allele does not correlate with the phase and the outcome of 
HBV infection. HBsAg and HBV-DNA levels at BL and HBsAg clearance in IFN +/-NA 
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treated pts were not influenced by the CC allele, although a faster HBV-DNA was found 
in HBeAg pos CC pts. These findings underline major differences in the mechanisms of 
natural and therapy induced control of HBV and HCV infections.  
 
 
 
 
 
 
 
 
1. INTRODUCTION 
 
 
 
1.1 HBV biology 
 
Human Hepatitis B virus (HBV) is classified as a member of the Hepadnaviridae family 
[Gust et al, 1986] (hepatotropic DNA viruses), that can be divided into two genera: the 
Orthohepadnaviruses, infecting only mammals, and the  Avihepadnaviruses infecting 
birds. To date, two major species have been assigned to the Avihepadnaviruses, the 
duck hepatitis B virus (DHBV) and the heron hepatitis B virus (HHBV). The 
Orthohepadnavirus genus includes the four best-known distinct species human hepatitis 
B virus (HBV), woodchuck hepatitis virus (WHV), ground squirrel hepatitis virus (GSHV) 
and woolly monkey hepatitis B virus (WMHV). The host range of Orthohepadnavirus 
varies in the different species allowing in some case the possibility to have more infecting 
animal models. WHV, is a well studied orthohepadnavirus that occurs naturally in 
marmots and cannot be transferred to other rodents like its relative GSHV [Summers et 
al., 1978; Mason et al., 1980]. GSHV can infect woodchucks, thus its host range is not as 
narrow as the WHV host range. Finally, the WMHV, despite having a non-human primate 
as its natural host, in contrast to HBV, is not infectious for chimpanzees [Lanford et al. 
1998]. 
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1.1.1 Morphology of HBV 
 
 
The infectious HBV virion (Dane particle) is spherical shaped and has a  diameter of 42-
47 nm. External envelope consists of a cell derived phospholipidic bilayer with three 
different surface protein embedded in it. These proteins, according to their size are 
named HB small surface antigen (HBsAg), middle (HBMAg), or large (HBLAg). The 
nucleocapsid, which forms the inner part of the Dane particle, is around 28 nm in size 
and contains a single copy of the circular partially double-strand genomic DNA which is 
covalently linked to the viral reverse-transcriptase (fig 1).   
 
 
 
 
 
 
 
 
 
 
 
 
 
      Fig. 1 – HBV structure  
 
The average size of the viral genome is around 3.2 kbp, varying slightly from genotype to 
genotype and from isolate to isolate. The viral genome encodes for the core protein 
(HBcAg), the pre-core protein also known as the e-antigen (HBeAg), the polymerase, the 
three surface proteins, and the X protein. 
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1.1.2 HBV Genome and Proteome 
 
 
The HBV genome is a relaxed circular, partially double stranded DNA of approximately 
3,200 base pairs. There are four partially overlapping open reading frames encoding the 
envelope (Pre-S/S), core (Precore/Core), Polymerase, and X proteins (fig. 2) [Tiollais et 
al. 1985; Seeger et al. 2000]. All open reading frames are in an identical orientation and 
overlap at least partially. Within the Dane particle the negative strand of the viral genome 
is present in full-length, thus carrying the whole genome. In contrast, the positive strand 
spans only ~ 2/3 of the genome in length, being its 3’-end is variable in size [Lutwick et 
al. 1977; Summers et al. 1975) . The viral polymerase is covalently bound to the negative 
strand by a phosphotyrosine bond. At the 5’-end of the positive strand a short RNA 
oligomer originating from the pre-genomic (pg) RNA remains residually bound covalently 
after the viral DNA synthesis. The negative strand, in contrast to the positive strand, 
contains on both the 5’-end and the 3’- end a small redundancy of 8-9 nucleotides in 
length, named the R-region. These redundant structures are essential for viral replication 
[Seeger et al. 1986; Will et al 1987; Lien et al. 1986]. The viral genome covers four open 
reading frames, all of them encoded by the negative strand, with 6 start codons, four 
promoters, two transcription enhancing elements, a poly-adenylation signal motif, and a 
number of signals for DNA replication. 
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 Fig 2- HBV genome organisation 
 
 
The major RNA transcripts are polyadenylated, capped and named pre-C/C, preS, and S 
mRNAs [Enders et al., 1985; Cattaneo et al., 1984]. Moreover, a 0.7 kb long mRNA 
termed X mRNA occurs occasionally. The 3’-end of all HBV transcripts is common for all 
of them and created by the polyadenylation signal in the core (C) gene. 
 
 
 
1.1.2.a  S gene/HBsAg  
 
 
The S gene encodes for the three distinct but related surface proteins termed S, M and L 
by a single open reading frame referred as ORF-E. This ORF is 389 or 400 codons in 
length depending on viral subtype and  consists of three 5′ in-phase ATG codons for the 
initiation of translation and one 3′ TAA termination codon. Thus, the three HBV surface 
proteins only differ by the length of their N-terminal domains and are essential for 
envelopment of nucleocapsids. All three envelope components are glycosylated, type II 
transmembrane proteins, that can form multimers stabilized by disulfide bridges formed 
by cysteine residues present in the S domain. The L protein is characterized by the 
addition of a 108 to 119 residue sequence named “PreS1” on the N-terminus of M. Thus, 
this large protein basically incorporates the preS domain (preS1 and preS2) to the N-
terminus of S [Heermann et al. 1984]. Currently, it is clearly recognized that L plays a 
specific role in the viral cycle: recruitment of a mature viral nucleocapsid for virion 
budding [Bruss, 2007] and recognition of the cellular (co-)receptor(s) for virus entry 
[Glebe and Urban, 2007], respectively. The 226 aa S protein traverses the membrane at 
least twice with transmembrane region 1 (TM1) and TM2 and is produced at the rough 
endoplasmic reticulum (ER) [Bruss, 2007].  The biosynthesis of the 281 aa M protein is 
9 
 
quite similar to S and has a similar topology. This protein differs from S by the N-terminal 
addition of a 55 residue sequence named “PreS2”. However, the exact role of M in the 
viral cycle remains unclear. Indeed, its in vivo absence in infected cells does not disrupt 
viral morphogenesis or particle functionality [Fernholz et al., 1991]. Thereby, this protein 
seems not to be essential for virus spread and its complete absence from the 
Avihepadnavirus genomes reinforces this hypothesis.  
S, L, and M proteins are all found as components of the Dane particles. However, the 
surface proteins are not only incorporated into virion envelopes but also form subviral 
spherical particles without nucleocapsids. These particles assemble at a pre-Golgi 
membrane [Huovila et al., 1992] together with lipid, have a diameter of 20 nm, and are 
spherical or filamentous in shape (fig.3). The Large surface protein is an essential 
component of both virions and filaments and represents 10% of their envelope proteins. 
In contrast, it represents only 1% of the 20 nm spherical particles. The M protein is 
present in equal amounts in Dane particles and filaments and constitutes 10% of the 20 
nm spherical particles.  S, by itself, is an essential component of virions, filaments and 
spheres (70-89%). Subviral HBsAg particles exceed virions by a variable factor of 102–
105 and can accumulate up to concentrations of several hundred micrograms per milliliter 
of serum in the blood of HBV-infected patients [Seeger et al., 2000]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   Fig. 3 – Morphology of HBV particles, HBs filaments and HBs spheres -  [adapted from: Molecular    
   Biology of Hepatitis B virus- Heermann KH and Gerlich WH-  CRC press (1991)] 
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In addition to the serum, HBsAg can be detected in the infected hepatocytes with 
different expression patterns according to the different phases of infection. It has been 
shown that there is membranous staining of HBsAg associated with variable degrees of 
cytoplasmic staining of HBsAg during the phase of active hepatitis B virus replication 
and, by the contrast, solely cytoplasmic staining of HBsAg during the non-replicative 
phase [Gudat et al., 1975; Ray et al., 1976; Montano et al., 1982]. Membranous staining 
of HBsAg on the hepatocyte correlated excellently with serum HBV-DNA and could be 
recognised as a marker of active hepatitis B virus replication [Chu et al., 1995]. 
 
 
 
1.1.2.b PreC/C gene/ HBeAg, HBcAg 
 
 
The PreC/C ORF contains two in-frame translation initiation signals separated by 28 
codons, thus encoding both precore protein,  precursor for the viral e antigen (HBeAg), 
and Hepatitis B virus core antigen (HBcAg) [Uy et al., 1985; Seeger et al., 1986]. 
Synthesis of precore protein is initiated from the first ATG and core protein from the 
second at positions 1814 and 1901 respectively. The precore protein therefore initially 
contains all of the core protein sequence plus 29 amino acids at its N-terminus. These 
constitute a signal peptide that directs the nascent chain to the endoplasmic reticulum 
and the secretion pathway.  
The first 19 amino acids are cleaved off and during transport to the cell surface the 
protein is further matured by removal of the highly basic C-terminal tail. Production and 
secretion are modulated at both transcriptional [Okamoto et al., 1994; Laskus et al., 
1994] and translational [Brunetto et al, 1989; Carman et al., 1989; Okamoto et al., 1990] 
levels and the protein is released as a soluble antigen, HBeAg [Standring et al., 1988]. 
HBeAg is not a structural component of the virion, it is not required for viral replication, 
however its secretion is conserved in both Orthohepadnaviruses and Avihepadnaviruses 
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and its synthesis is tightly regulate at transcriptional and translational levels.  This it is 
supposed to be due to an immune-regualtory function promoting  virus persistence by 
inducing neonatal tolerance and modulating the immune-response in adults  [Chang et 
al., 1987; Chen et al., 1992, Milich et al., 1997]. The core protein which itself can be 
phosphorylated by several kinases, is essential for the formation of nucleocapsids. It 
plays an active role in binding and packaging of the pregenomic RNA, recruitment of the 
viral polymerase, and thus enables the RT-polymerase/RNA complex to initiate reverse 
transcription within the newly forming nucleocapsids [Lan et al., 1999; Gerlich et al., 1982 
1982; Watts et al.,  2002]. Although HBcAg and HBeAg show substantial amino acid 
sequence homology, they are serologically distinct, and the immune responses to these 
antigens appear to be regulated independently. HBcAg is highly immunogenic (0,025 mg 
of HBcAg elicit antibodies production) and functions as both T-cell independent and T-
cell dependent antigen. Immunization with HBcAg preferentially primes Th1 cells; and 
HBcAg-specific Th cells mediate anti-envelope as well as anti-HBc antibodies 
production. 
HBcAg is a major target of CTL response. High levels of soluble anti-HBc, as observed in 
most of HBV infected individuals, may compete with B cells Ig receptor mediated  uptake 
of HBcAg with inhibition of TH cell activation. The immune response to HBeAg is strictly 
T cell-dependent [ Milich et al., 1986] and HBeAg preferentially, but not exclusively, 
elicits Th0 or Th2-like cells which stimulate the humoral immune reaction [Milich et al., 
1997].  In particular, HBeAg-specific Th2 cells may cross-regulate HBcAg-specific Th1 
cells or the secreted HBeAg may preferentially behave as a tolerogen and inactivate 
HBcAg-specific T cells through deletion or clonal anergy in the periphery [Chen et al., 
2005; Milich, 1997; Milich et al., 1998]. T-cell anergy is a tolerance mechanism in which 
the T cell is functionally inactivated following an initial antigen encounter but remains 
alive in a hypoactivated state. 
 
 
 
1.1.2.c P gene/Polymerase 
 
 
The P ORF, covering nearly 80% of the hepadnaviral genome (1685 nt), encodes a 
multifunctional protein including the terminal protein (TP) that acts as a primer for HBV 
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DNA synthesis and the viral polymerase that possesses DNA polymerase, reverse 
transcriptase (RT) and RNaseH activities. During replication, a pre-genomic RNA is 
produced that encodes for both HBcAg and polymerase [Nassal et al. 1996; Nassal 
1999]. Polymerase is the second ORF on this messenger RNA (mRNA) and partially 
overlaps with the 3’ end of the HBcAg cistron. The HBV polymerase is not proteolytically 
cleaved to mature enzymatically active proteins, but consists of 4 domains [Lanford et al. 
1999]: a TP domain, which becomes covalently linked to negative-strand DNA during 
initiation of reverse transcription [Weber e al. 1994; Zoulim et al. 1994] a spacer domain, 
which is very tolerant to mutations and can be partially deleted without affecting 
polymerase activity [Li et al. 1991; Radziwill et al. 1990; Kim et al. 1999]; the reverse 
transcriptase/polymerase (RT domain), which contains the conserved regions A through 
F, characteristic of RNA-dependent RNA polymerase (RdRP) and RNA-dependent DNA 
polymerase (RdDP) [Poch et al. 1989; Lesburg et al. 1999]; and the ribonuclease H 
domain (RH domain)[Wei et al. 1996].  
 
 
 
1.1.2.d X gene/X protein 
 
 
The X ORF is located downstream to enhancer 1 (Enh I) and is partly overlapped by the 
P  ORF at its N terminus and by the PreC/C  ORF at its C terminus [Tiollais et al. 1985]. 
Furthermore, the X ORF is overlapped by several cis-elements including enhancer II 
(Enh II) [Yee, 1989], several cis-elements for transcriptional regulation, and the PreC-C 
promoter. The X gene is transcribed independently of the other viral transcripts  and a 
separate X mRNA of 0.8 kb has been detected in liver tissues of both human and 
woodchuck [Kaneko et al.,1988; Guo et al., 1991] as well as in transgenic mice [Kim et 
al., 1991]. So far, the role of the X protein is not fully understood, indeed, although HBx 
does not bind DNA, the first activity identified for this viral protein was the ability to 
activate transcription of viral and cellular genes [Twu et al., 1987]. HBx is a weak 
transactivator, but it is capable to activate a variety of cellular and viral promoters. This 
broad spectrum of activities relies on two different mechanisms: either direct interaction 
with nuclear transcriptional regulators, or activation of signal transduction pathways [Wei 
et al., 2010]. HBx has also been implicated in pleiotropic activities such as cell cycle 
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regulation, activation of signaling pathways, modulation of apoptotic pathways, and 
inhibition of DNA repair [Andrisani et al. 1999; Bouchard et al., 2004; Tang et al. 2006;]. 
 
 
 
1.1.3 HBV life cycle 
 
 
Hepatocytes are the primary site of viral DNA replication. It is assumed that viral entry 
and the host range of hepadnavirus is dependent on the N-terminus of the large surface 
antigen [Ishikawa et al., 1995; Chouteau et al., 2001; Lambert et al., 1990; Gripon et al., 
2005; Urban et al., 2002]. So far, the intrinsic HBV receptor has not been discovered, but 
from studies on DHBV in primary duck hepatocytes it is assumed that around 104 
receptor molecules per cell mediate the rapid binding, followed by a slow uptake of the 
virus to the cell which can take up to 16 hours [Pugh et al.,1989; Klingmuller et al.,1993; 
Pugh et al., 1995]. Following entry the nucleocapsid is transported into the cell nucleus, 
where the viral nucleic acid is released. Release of the viral DNA and disintegration of 
the nucleocapsid is assumed to take place at the nuclear core complex [Kann et al., 
1997; Rabe et al., 2003]. 
The life cycle of hepadnaviruses is characterized by the synthesis of a 3-kb partially 
double-stranded, relaxed-circular DNA (rcDNA) genome by reverse transcription of an 
RNA intermediate, the pregenome.  The mechanism of RNA-directed DNA synthesis has 
been well characterized [Ganem et al., 1994; Seeger et al., 1996]. After virus penetration 
the DNA reaches the nucleus and is immediately converted by host enzymes to 
complete open circular double-stranded DNA and then to supercoiled DNA (cccDNA).  
Since cccDNA, which accumulates only in the nucleus, is the template for the 
transcription of all viral mRNAs, its formation indicates a successful initiation of infection. 
The viral RNAs include pregenomic RNA (pgRNA), which serves as the template for 
reverse transcription, as well as three subgenomic mRNAs necessary for the translation 
of the envelope proteins and the mRNA for the X protein. The pgRNA is both the 
template for core and polymerase protein translation and is the matrix for the progeny 
genomes. The pgRNA bears a secondary structure - named ε-structure - that is present 
at both the 5’- and the 3’-ends. The ε-hairpin loops at the 5’-end are first recognized by 
the viral polymerase and act as the initial packaging signal [Bartenschlager et al., 1992; 
14 
 
Hirsch et al., 1990; Huang et al., 1991] (Fig.4). In the cytoplasm, the core protein forms 
the basis for the nucleocapsid. It plays an active role in binding and packaging of the 
pregenomic RNA, recruitment of the viral polymerase, and thus enables the RT-
polymerase/RNA complex to initiate reverse transcription within the newly forming 
nucleocapsids.  Finally, in the endoplasmic reticuluum, the nucleocapsid acquires the 
external coat. In the early stages of infection the nucleocapsid is also transported to the 
nucleus in the hepatocyte to increase cccDNA copies [Nassal et al., 1993; Nassal et al., 
2000]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
     Fig.4  –  
 
 
HBV-DNA is able to integrate into the host genome. The integration occurs in different 
sites and usually affects only one part of the viral genome, which retains the ability to be 
transcribed. The integration of HBV-DNA is an early event in the natural history of 
infection and is implicated in the pathogenesis of hepatocellular carcinoma: the 
integration within or near cellular genes involved in regulating cell cycle, could result in 
an alteration of their function promoting in the hepatocytes affected a neoplastic 
transformation. 
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1.1.4  Viral Heterogeneity 
 
 
Changes in the viral genomes occur randomly as errors in the replication. These can be 
nucleotide substitutions (point mutations), deletion or insertions. Usually DNA viruses 
have a more stable genome than those RNA,  because of the proofreading capacity of 
the host enzyme that they exploit for replication. The Hepadnaviridae genome represent 
an exception. Although their genome is a double-strand DNA, these viruses replicate 
through a RNA template which is reverse transcribed by a enzymatic complex that lacks 
the proofreading capacity. On the other hand, the HBV genome in particular, has a  very 
compact organization and even a single nucleotide substitution may result in pleiotropic 
effect. For this reason, the number of mutations that can be tolerated without losing 
infectivity and replication capacity is rather limited. [Miller et al., 1989]. Indeed, any 
mutant selection is related to its biological efficiency and ability to escape immune 
pressure, both humoral and cellular, and/or selective pressure exerted by antiviral drugs 
that directly interfere with viral enzymes. Moreover, in chronic hepadnavirus infections, 
net virus expansion cannot occur indefinitely. The maximum amount of virus, or viral 
cccDNA, in the liver is limited by the number of hepatocytes that can be infected and the 
maximum number of cccDNA copies per hepatocyte. In a fully infected liver, new 
cccDNA synthesis is prevented unless uninfected cells are generated by liver growth or 
cell turnover or unless existing cccDNA molecules are lost and replaced within the cell. 
Turnover of cells or cccDNA thus provides an opportunity for enrichment of one virus 
strain over another through competitive growth [Zhang et al., 2000]. This explains why, 
despite the relatively high mutation rate of HBV (approximately 2 x 104 nucleotide 
substitutions/site/year), only a small proportion of mutants can survive [Girones et al., 
1989].  
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1.1.4.a S Mutations 
 
 
The envelope proteins of HBV are targets of both humoral and cellular immune response 
that are involved in viral clearance. Anti-HBs antibodies show neutralizing activity and 
are essential to limit the spread of the infection. As a consequence, envelope proteins 
have been used in the prophylaxis of HBV infection for preparation of the vaccines and 
production of antibodies for therapeutic purposes [Neurath et al., 1986; Vento et al. 1987; 
Nayersina et al.,1993; Jin et al., 1995]. Some of the envelope mutants determine the 
different subtypes of HBV and may have been selected over centuries perhaps under 
HLA pressure.  
In recent years, many variants have been identified, whose mutations produce changes 
in the epitopes recognized by the current diagnostic assays and determine the 
undetectability of the variant by some of the commercially available HBsAg assays 
[Carman et al., 1995; Carman et al., 1997]. Most frequently, point mutations occur in the 
area of the “a” determinant (124-147 aa), and also the immune response induced by 
recombinant vaccines that are current available seems to focus on this region as target. 
The first “vaccine escape mutant” described [Carman et al., 1990] was substitution of a 
Gly residue at position 145 by an Arg residue (G145R), which has been identified also in 
chronic carriers [Carman et al., 1990]. Many other substitutions in the “a” determinant 
(I/T126A/N, A128V, Q129H/R, G130N, M133L/T, K141E, D144A/H) have since been 
associated with immune escape [Cooreman et al., 2001], but G145R is by far the most 
common variant.  Immune escape mutants with substitutions outside of the “a” 
determinant have also been described [Oon et al., 1999], the most important of which is 
P120S/T and the loss of cysteine 124 abolishing HBsAg secretion in a HBsAg 
negative/HBV-DNA positive patient. The other medical condition associated with the 
emergence of envelope variants is treatment with monoclonal antibodies or 
hyperimmune human immunoglobulin (HBIG) which is used to prevent HBV recurrence 
in patients transplanted for HBsAg- positive cirrhosis. Similar to vaccine recipients, a 
glycine/arginine substitution at position 145 and aspartic acid/alanine at aa 144, are the 
most common variants found in these cases [Carman et a., 1996]. Another mutant 
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described in a HBsAg negative/HBV-DNA positive patient was the loss of cysteine 124, 
abolishing HBsAg secretion.  
Many mutations affect the PreS domains of the envelope proteins, most of which are 
deletions [Kay et al., 2007]. PreS mutants emerge in chronic infections, often in patients 
treated with interferon  [Gerner et al., 1998; Santantonio et al., 1992], and probably 
represent attempts by the virus to evade host immune responses. The emergence of 
pre-S mutants could play a role in viral persistence; however, their implication in the 
pathogenesis of liver damage cannot be excluded [Brunetto et al. 1999]. The region of 
the S gene coding the PreS1 and PreS2 domains is overlapped by the region of the P 
gene coding the spacer domain of the viral polymerase. This domain gives flexibility to 
the viral polymerase, but its sequence is not absolute and can suffer in-phase deletions 
and insertions without affecting the enzymatic activities of the protein. However, there 
are constraints on PreS1 mutations due to the fact that its N-terminus (residues 21–47 of 
the genotype D PreS1) is important in viral attachment to hepatocytes [Neurath et al., 
1986] and the S promoter is located in the 3’ extremity of the PreS1 coding region. In 
addition, some mutations can result in intracellular retention of the PreS1 protein [Bock et 
al., 1997; Melegari et al., 1994] which inhibits virion secretion and is cytotoxic. As a 
result, although PreS1 deletion mutants are replication competent, they usually need a 
helper virus and are found as minor viral populations. On the other hand, there appear to 
be few constraints on PreS2 mutations since its product is not essential for viral 
replication, particle morphogenesis and secretion and infectivity [Fernholz et al., 1991]. 
Mutations include deletion or missense mutation of the PreS2 ATG, thereby abrogating 
synthesis of the protein, and deletions or alterations of B- and T-cell epitopes. HLA class 
I-restricted, cytotoxic T cells recognize short viral peptides that are generated by the 
intracellular processing of endogenously synthesized viral antigens within infected cells, 
and are expressed at the cell surface in the binding groove of selected HLA class I 
molecules. Single amino acid substitutions of MHC anchor residues or TCR contact sites 
have been shown to abrogate CTL responses in vitro by inhibiting either HLA binding or 
TCR recognition of the peptide. The most common mutation affecting the PreS2 region 
involves the first part in which is  MHC class I-restricted T-cell epitope [Bertoletti et al, 
1994; Chisari et al., 1995; Sobotta et al., 2000; Fan et al., 2001;]. An association 
between pre-S2 mutant (start codon mutants preventing pre-S2 protein synthesis) 
infection  and fulminant hepatitis has been described, and a direct role of these variants 
in the induction (via an abnormal immune response or a direct cytopatic effect) of severe 
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liver damage has been hypothesized [Pollicino et al., 1997]. Mutations in the S gene may 
lead to different histological liver features. Glassy or ground glass hepatocytes (GGH) 
ultrastructurally are characterized by an abundance of smooth endoplasmic reticulum 
(ER), among which HBsAg is accumulated and are different in morphology and 
distribution at different replicative stages of chronic HBV infection [Hadziyannis et al., 
1973] . Recently, intracellular study have revealed that ground glass hepatocyte may 
contain specific mutants and exhibit differential biological activities [Wang et al., 2003; Su 
et a., 2008].  Type I GGHs expressed an inclusion- like pattern of hepatitis B surface 
antigens and harbored mutants with deletions over pre-S1 region, whereas type II GGHs, 
distributed in clusters and emerged at late replicative phase, contained mutants with 
deletions over pre-S2 region that defines a cytotoxic T lymphocyte (CTL) immune 
epitope, and may represent an immune escape mutant. 
 
 
 
1.1.4.b PreC/C Mutations: HBeAg defective Mutants 
 
 
During chronic HBV infection, two major types of HBV core gene variants frequently 
occur that affect the expression of HBeAg: the PreCore (PC) mutants and the basal core 
promoter (BCP) mutants.  
As described above, the secretion of the antigen "e" depends on the expression of a 
specific leader peptide which is encoded by  HBV pre-core. In 1989 two independent 
studies performed in anti-HBe positive patients of the Mediterranean area showed that 
the most frequent cause of the discrepancy between the presence of HBV DNA and the 
absence of HBeAg was the infection with HBV variants unable to secrete the soluble 
form of the HBV nucleocapsidic protein (HBeAg minus mutant)[Brunetto et al, 1989; 
Carman et al., 1989]. The HBeAg production and secretion are modulated both at the 
transcriptional [Okamoto et al. 1994; Laskus et al., 1994, Jaw et al., 1991] and 
translational levels [Brunetto et al., 1989, A; Carman et al., 1989, Okamoto et al., 1990, 
Raimondo et al., 1990; Brunetto et al., 1999]. The most prevalent PC mutation that affect 
the HBeAg expression at the translational level, is a guanine to adenine transition at 
nucleotide position 1896 (G1896A), which creates a TAG stop codon at codon 28 of the 
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PC protein [Brunetto et al., 1989; Carman et al, 1989; Raimondo et al., 1990; Ganem et 
al., 2001](fig 5 ). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
- Fig. 5  Nucleotide composition of epsilon signal 
 
However, this mutation is located within the epsilon (ε) structure, a highly conserved 
stem-loop essential for initiation of encapsidation within the viral replication cycle. In 
order to stabilize this ε structure, the nucleotide at position 1896 is paired with the 
nucleotide at position 1858, which naturally is a thymidine (T) in genotypes B, C, D, E, 
and G and a cytidine (C) in genotype A. Therefore, in HBV genotype A, the G1896A 
mutation usually arises together with a C1858T nucleotide exchange [Lok et al., 1994; 
Rodriguez-Frias et al., 1995]. These HBV mutant, termed HBeAg minus or defective is 
predominant, in the mediterranean area, in 90% of HBV chronic carriers anti-HBe 
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positive [Brunetto et al, 1989; Raimondo et al., 1990; Kojima et al., 1991; Santantonio et 
al., 1992; Tong et al, 1992]. As previously shown, wild-type and HBeAg minus HBV may 
coexist in a HBV carrier and their relative ratio vary over time [Brunetto et al., 1991; 
Brunetto et al., 1993; Brunetto et al., 1994; Brunetto et al., 1994b; Brunetto et al., 1997]. 
Furthermore, as discussed later, follow-up studies suggested the important association 
between different ratios of circulating wild type and HBeAg minus HBV and pathogenetic 
events during the course of chronic hepatitis B [Brunetto et al., 1994; Brunetto et al., 
1997]. In vitro experiment showed that the precore region and pgRNA transcription are 
under control of regulatory elements such as the Basic Core Promoter (BCP) and the 
Core Upstream Regulatory Sequence (CURS) [Yuh et al., 1992]. Mutations in these 
domains appear to affect mRNA transcription, notably by decreasing the synthesis of 
HBeAg [Okamoto et al., 1994]. Cytokines,  such as tumor necrosis factor alpha (TNF-) 
and interferons alpha and gamma (IFN- and γ), held the transcription inhibitory activity 
by acting directly on BCP [Romero et al., 1996].  
Other mutations that act at translational level are a thymine (T) instead of a cytosine (C) 
at nucleotide 1817 and an A instead of a G to 1897, both of which give rise to 
translational stop codons.  Two mutations were also observed: G⇨T and T⇨C in in 
position 1816 and 1815 respectively, responsible for the elimination of translation start 
codon of the pre-core region. All these mutations leads to the same result: a defetive 
virus of “e” antigen [Brunetto et al, 1989; Carman et al., 1989 Santantonio et al., 1992; 
Tong et al, 1992].  
The most common BCP mutation is the double A1762T and G1764A nucleotide 
exchange, which results in a decrease of HBeAg expression of up to 70% but enhanced 
viral genome replication [Buckwold et al., 1996; Hunt et al., 2000; Locarnini et al., 2003]. 
Moreover, considering the regulatory activity of these region, carriers infected with HBV 
with the BCP mutations resulting in gene deregulation, may be at increased risk for 
hepatocellular carcinoma [Lee, 1997].  
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1.1.4.c P Mutations 
 
 
Mutations in the P gene especially occur following prolonged treatment with drugs 
interfering with that acting on polymerase activity, nucleos(t)ide analogues in particular. 
Resistant mutants developed under treatment, showed changes in conserved patterns or 
domains essential for viral DNA replication.  Polymerase domain are A, B, C, D, E and B, 
C, D are the most affected by mutations. The first resistant mutants have been identified 
in domain C, where the amino acid methionine (M) at position 204 (numbering according 
to the nomenclature proposed in 2001 by Stuyver et al.) is replaced by valine (V) or 
isoleucine (I) , rtM204V or I [Tisdale et al., 1993, Ling et al., 1996, Perillo et al., 1996; 
Bartholomeusz et al., 1997, Carman, 1997; Locarnini, 1998]. These mutations were first 
identified in patients undergoing lamivudine treatment, where appeared frequently 
associated with compensatory mutations (or rtL80V I rtV173L, rtL180M or C) increase 
either replication efficiency or antiviral resistence [Delaney et al. 2003; Nakanishi et al. 
2005; Pai et al. 2005, Warner et al. 2007]. The mutation rtN236T  is  a primary mutations 
in the D domain that has been associated with resistance to Adefovir and Tenofovir 
[Angus et al. 2003].  Another primary mutation able to determine resistance to Adefovir 
and Tenofovir is located in the B domain  and is rtA181V or T or S [Fung et al. 2005; 
Moriconi et al., 2007]. In addition, many other mutations have been associated with 
reduced susceptibility: rtV84M rtS85A in the A, rtP237H rtN238T or D in the D domain 
and rtV214A, rtQ215S in between C and D domains.  Drugs that require the 
development of multiple mutations in the Pol gene to show restitance are defined with 
“high genetic barrier”. Patients that show simultaneously rtM204I o V and rtL180M 
develop resistance to entecavir if one of the following mutations is added: rtI169T, 
rtT184G, rtS202I, rtM250V [Tenney et al. 2004]. 
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1.1.4.d X Mutations 
 
 
Mutations in the X region may involve replication regulatory elements such as core 
promoter (CP) and enhancer II: three AT-rich regions are present in CP, each of them 
would represent an independent binding site for liver-enriched factors for initiating the 
transcription of the different 3.5 mRNAs [Lopez-Cabrera et al., 1990]. CP mutations are 
located most frequently in the second AT-rich region (1762 A to T switch and 1764 G to 
A switch); occasionally, point mutations have been described in the first AT-rich region, 
whereas no mutations have been observed in the third region, which could induce a 
decrease in the transcription of genomic mRNA [Okamoto et al., 1994;  Sato et al. , 
1995]. In fact, it has been shown that point mutations in the TATA box of eukaryotic 
promoters drastically decrease in vitro transcription, and mutations in the AT region of 
viral promoters should have similar effects [Corden et al., 1980].  
 
 
 
1.1.5.e Genotype and Geographical distribution 
 
 
Genotypes or genetic subtypes are genetically related strains and have been described 
for viruses belonging to several different families. Four genotypes, A–D, of HBV, 
originally designated as genomic groups, were based on > 8% intergenotype and <4% 
intragenotype divergences, when 18 complete genomes were compared [Okamoto et al. 
, 1988]. Later research has identified other four HBV genotypes, E–H [Norder et al., 
1992; Norder et al. 1994; Naumann et al 1993; Stuyver at al. 2000; Arauz-Ruiz et al. 
2002]. Two genotypes, A and F, have been further subdivided into subgenotypes 
identified by arabic numerals [Kramvis et al., 2002; Kimbi et al. 2004, Norder et al. 2003]. 
The eight genotypes identified to date, are distributed in different geographical areas. 
Genotype A is present in North Europe and North America, genotypes B and C are 
typical of the East Asian countries, genotype D is spread all over in the world but mainly 
in the mediterranean area, genotype E is most common in Africa, F and H are endemic 
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of South and Central America  respectively, finally genotype G was firstly isolated in 
France but is rare and always found in coinfection with other genotypes (mainly A). HBV 
genotypes may influence the course of disease and among these relevant biological 
differences has  been recognised. The classical precore (PC) mutation, located at HBV 
nucleotide 1896 consisting of a G-A substitution that creates a stop codon, is not found in 
genotype A. Genotype A (and F2) contains a cytosine at position 1858 instead of a 
uracil, that stabilizes the PC loop, not allowing the 1896 G-A PC mutation to occur [Li et 
al., 1993].  Indeed, the HBV genotypes B, C, D and E are predisposed to develop the 
mutation at 1896 PreCore, which will result in an earlier seroconversion to anti-HBe. 
Genotype A (presumably A2) infection was associated with a significantly higher 
cumulative rate of sustained biochemical remission, HBV DNA clearance, and HBsAg 
clearance in patients with chronic HBV infection than genotype D infection [Sanchez-
Tapias et al., 2002]. Multiple studies have shown that patients with genotype C 
experience HBeAg seroconversion at an older age and are more likely to be HBeAg 
positive at any given age than HBV genotype B [Chen et al., 2004; Kao et al., 2002; Kao 
et al., 2004]. HBV genotype C is associated with an increase risk of liver inflammation, 
flares of hepatitis, liver fibrosis, and cirrhosis. Persons infected with genotype D usually 
convert from HBeAg to anti-HBe in adolescence or early adulthood. The Pre Core mutant 
is frequently associated with HBV seroconversion in this genotype. While it appears that 
many persons go into and remain in the inactive carrier phase, some persons develop 
HBeAg-negative/anti-HBepositive chronic hepatitis B. This can lead to cirrhosis and HCC 
[Naoumov et al., 1992; Grandjacques et al., 2000; Hadziyannis et al., 2001; Brunetto et 
al., 2002; McMahon, 2005; Zacharakis et al.,2005]. Genotype F is divided into four 
subtypes: F1–F4 [Devesa et al., 2008]. Genotype F2 codes for C at position 1858 and 
therefore PC mutation does not occur, whereas F1 does not and thus PC mutation can 
occur [Schaefer, 2005].  
 
 
1.2 Hepatitis B virus infection and disease  
 
 
HBV can cause a transient or chronic liver disease. The transient or acute infection may 
be mild and asymptomatic or causing an acute hepatitis with varying degrees of severity 
to result in 0.5% of patients with fulminant hepatitis. There is no evidence that HBV is 
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directly cytopathic for the infected hepatocyte [Guidotti et al., 1995; Chisari et al., 2000; 
Guidotti et al., 2006]. Therefore, hepatocellular damage is believed to be induced by the 
host immune reaction.  Correlative clinical studies show that in acute, self-limited 
hepatitis B, strong T-cell responses to many HBV antigens are readily demonstrable in 
the peripheral blood [Chisari et al., 1995]. These responses involve both major-
histocompatibility-complex (MHC) class II–restricted, CD4+ helper T cells and MHC class 
I–restricted, CD8+ cytotoxic T lymphocytes. By contrast, in chronic carriers of HBV, such 
virus-specific T-cell responses are greatly attenuated, at least as assayed in cells from 
the peripheral blood. It has been show that the resolution of infection occurs through the 
coordinated activity of cytokines (INF g and TNF a)  released by lymphocytes and the 
cytolitic response that leads to infected hepatocytes elimination [Ando et al., 1994; 
Guidotti et al., 1994a; Guidotti et al., 1994b; Guidotti et al., 1996; Guidotti et al., 1999a; 
Guidotti et al., 1999b; Guidotti et al., 2000; Kakimi et al., 2001; Tsui et al., 1995]. The 
natural history of chronic HBV infection develops over decades, the subject is often 
infected at birth or early in life and keeps for several years a state of tolerance or weak 
activation during which the level of liver damage is minimal compared to high replication. 
Indeed, it is assumed that an “immune-tolerant” conditions it is established in those 
cases in which the host immune system is compromised or does not recognise the viral 
antigens (i.e., if the exposition to the virus occurs during the intrauterine life) [Milich et al., 
1990]. This condition is common in childrens borned from HBeAg-positive mothers and 
infected with HBV in the perinatal period [Lee et al., 1990; Bortolotti et al., 1990; Moyes 
et al., 1993]. In this case, the  exposure during pregnancy to circulating HBeAg promotes 
a tolerance state towards viral nucleocapsid antigens (HBcAg and HBeAg), which is the 
main target of cell-mediated response. The immune-tolerant phase can last for a few 
years to more than 30 years [Hui et al., 2007]. During this phase, the markers of infection 
(HBsAg and anti-HBc) and replication (HBeAg and HBV-DNA), are present in the sera of 
infected individuals whereas are absent those of virus-induced damage (IgM anti-HBc ). 
In the liver there is either no or minimal liver inflammation or fibrosis, a high percentage 
of hepatocytes express hepatitis B core antigen, predominantly in the nuclei, while 
HBsAg show an extensive membranous staining.  
Once the viral antigens are recognised by the immune system, the attempt to control the 
infection through the block of viral replication (cytokine-mediated) and infected 
hepatocytes elimination (cell-mediated) begins. Liver infiltration by lymphocytes, 
observed during viral hepatitis, is the main pathogenetic moment. These phase, termed 
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“immune-activation”, can persist for years with alternating phases of exacerbation and 
remission. In the serum are present markers of viral replication, with typical fluctuations 
in viremia levels, of liver damage and of virus-induced liver damage [Brunetto et al., 
2001]. In the liver the expression of HBcAg appears to be focal in the nucleic or  
cytoplasmatic whereas HBsAg stains mainly in the cytoplasm either in perinuclear blush 
to a dense signal corresponding to ground-glass cells. Most frequently, the immune 
activation leads to an inactive hepatitis B phase, characterized by the absence of HBeAg 
and the presence of anti-HBe, normal ALT levels, low HBV DNA levels (<2000 IU/ml), 
and absence or minimal liver fibrosis and inflammation [De Franchis et al., 1993; 
Martinot-Peignoux et al., 2002; Zacharakis et al., 2005]. However, a signifcant proportion 
of patients, after seroconversion, retain evidence of viral replication and virus-induced 
liver damage. This condition is tipically associated with the prevalence of a viral 
population unable to secrete the HBeAg [Bonino et al., 1981; Bonino et al., 1986; 
Brunetto et al., 1989b; Ulrich et al., 1990; Bonino et al., 1991; Brunetto et al., 1991; 
Bortolotti et al., 1993; Brunetto et al., 1994; Hadzyannis, 1995; Brunetto et al., 1997; 
Brunetto et al., 2001; Brunetto et al., 2002]. This HBeAg defective mutant has been 
demonstrated during the exacerbation of the immune elimination phenomena preceding 
HBeAg seroconversion to anti-HBe, becoming the majoritary viral population in the HBe 
negative/anti-HBe positive chronic hepatitis B, which is prevalent in patients infected with 
genotype D of HBV in the Mediterranean area.  The disease caused by HBeAg minus 
HBV runs usually asymptomatic for three to four decades and reaches the stage of 
histologic cirrhosis at a median age of about 45 years [Brunetto et al., 2002]. Thereafter 
cirrhosis progresses to end stage complications in about 25% of patients in about 10 
years; recurrent hepatitis B exacerbations accelerate disease progression [Brunetto et 
al., 2002].  
Hepatitis B  “e “antigen (HBeAg)-negative Hepatitis B virus (HBV) carriers represents the 
great majority of cases of serological and clinical standing in many geographical areas, 
including Europe, having became more prevalent during the last decade because of the 
aging of the HBV infected population [ Hadziyannis S, Papatheodoridis GV, 2006 ; Zarski 
JP, Marcellin P et al, 2006].  On the basis of the biochemical and virological profile, 
HBeAg-negative carriers can be classified as inactive carriers (normal ALT; HBV-DNA 
persistently ≤ 2000 IU/mL), with a survival comparable with the noninfected population, 
at least in Western countries [De Franchis R, Meucci G, Vecchi M et al, 1993 ; Manno M, 
Camma C, et al, 2004] ; active carriers (AC1) with normal ALT, HBV-DNA levels 
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persistently below 20000 IU/mL  and absence of significant liver disease HBV-induced; 
active carriers (AC) with viremia ≥ 20000 IU/mL independently of ALT values and 
different stages of liver disease [Brunetto et al, 2010] .  
Persistent viral replication is a major cause of chronic liver damage and development of 
cirrhosis: in a cohort study after a mean follow-up of 10 years about 50% of the patients 
with chronic hepatitis at baseline developed cirrhosis and persistently detectable HBV 
DNA was a factor independently associated with disease progression [Brunetto et al., 
2002]. Further, cirrhosis development as an end point complication was associated with 
recurrent hepatitis exacerbations [Brunetto et al., 2002]. 
Active carriers have a significantly increased risk of life-threatening liver complications 
such as hepatic decompensation, liver cirrhosis and hepatocellular carcinoma (HCC) 
[Beasley, 1988]. HBV infection appears to play both an indirect (via liver cirrhosis) and 
direct role in hepatocellular carcinoma development: the mechanisms of direct HBV 
oncogenesis are not completely understood, nevertheless either integration of HBV 
genomic DNA into cellular chromosomes, with disregulation of cellular gene function and 
transactivating activity of some HBV proteins (such as HBx and HBs truncated forms) 
had been shown to alter cellular homeostasis.  
Antiviral treatments currently available can slow disease progression in case of cirrhosis 
and lead to the cure of chronic hepatitis in patients with less advanced stage of fibrosis. 
Several baseline and on-treatment parameters, either virological or related to the phase 
of HBV infection (viral genotype, HBV-DNA levels, quantitative serum HBsAg levels, etc) 
can affect the outcome of antiviral treatment and to amend the natural history of HBV-
induced liver disease. 
 
 
1.2.1 Diagnosis of HBV infection 
 
 
Virological diagnosis and monitoring of hepatitis B virus infection are based on serologic 
assays detecting specific anti-HBV antibodies, and assays that can detect, quantify or 
characterize the components of HBV viral particles, such as HBV DNA and various viral 
antigens. Before the polymerase chain reaction (PCR) revolution,  HBV DNA was 
detected by molecular hybridisation using nucleic acid probes. The sensitivity of these 
techniques was limited to hundreds of thousands of virions [Bonino et al., 1981; Bonino, 
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1986b]. Now, amplifying a target nucleotide sequence with the most sensitive 
techniques, can even lead to the detection of viruses in individuals who are negative for 
other conventional viral markers [Raimondo et al., 2003]. The presence of HBV DNA in 
peripheral blood is a reliable marker of active HBV replication and reflect the viral activity 
within the liver.  However, the diagnosis of the infection  does not necessary imply that 
the liver is damaged by the virus. As described above, florid virus replication can persist 
for years without liver damage if the host's immune system does not react against viral 
antigens [Bonino et al., 1991b; Brunetto et al., 1991b]. Liver disease begins as soon as 
immunotolerance is lost and the virus infected cells start to be eliminated, therefore 
hepatitis B represents an injurious way of recovering.  Serum IgM anti-HBc are detected 
in any form of liver disease caused by HBV, independent on the duration of virus 
infection. Serum anti-HBc IgM are usually detected with high titers during an acute 
hepatitis B, and with lower titers after the typical flare-ups of alanine aminotransferase 
(ALT) which occur in chronic hepatitis. These episodes of ALT flare up are preceded by 
an increase or reappearance of viraemia [Colloredo et al., 1992] followed by rapid 
decline, whereas the elevation of IgM anti-HBc persist for a longer period due to their 
extended half life.  
HBsAg has been recently shown to represent a new diagnostic tool in the management 
of HBV infection. HBsAg serum levels vary during chronic hepatitis B infection, becoming 
lower during the transition from the active to the inactive phase of HBV infection [Nguyen 
et al 2010; Jaroszewicz et al., 2010; Brunetto et al., 2010]. Recent findings confirm that 
serum HBV-DNA and HBsAg levels provide complementary information on the status of 
HBV infection and  showed that the single point combined quantification of HBV-DNA 
(<2000 IU/mL) and HBsAg (<1000 IU/mL) allows the identification of inactive carrier with 
a very high diagnostic accuracy (94.3%) that is comparable with that of 1-year monthly 
monitoring [Brunetto et al., 2010]. HBsAg serum levels were shown to correlate with 
intrahepatic covalently closed circular DNA (cccDNA) levels [Volz et al., 2007] that vary 
in different patient populations but persist through all phases [Werle-Lapostolle et al, 
2004].  
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1.2.2 IL28B polymorphism  
 
Genetic polymorphisms located upstream of IL28B (IFN λ) gene are strongly related to 
HCV clearance after primary infection and response to Peg-IFN and Ribavirin in chronic 
HCV (particularly in genotype 1) patients [Honda M, Sakai A, et al, Gastroenterology 
2010; Urban TJ, Thompson AJ et al, Hepatology 2010; Thompson AJ, Muir AJ, et al, 
Gastroenterology 2010; Fischer J, Bohm S et al, Hepatology 2012]. Thus, IL28B 
polymorphisms are used as genetic markers of the ability of Interferon (IFN) to induce an 
intracellular antiviral response and are associated with spontaneous and treatment 
induced HCV clearance, whereas their role in HBV infection is still debated [Sonneveld 
J.M. et al, 2012; Lampertico P. et al, 2012; Mangia A, 2011]. 
 
 
 
2. AIM OF THE STUDY 
 
 
 
Transition from Active to inactive Chronic HBV infection (defined as HBV-DNA 
persistently < 2000 IU/ml) and HBsAg clearance are associated with better clinical 
outcomes. Both conditions can be achieved either spontaneously or after antiviral 
therapy. 
Aim of our study was to analyse in a large cohort HBV carriers the correlations between 
IL28B polymorphism (rs 12979860; CC alleles vs CT and TT alleles) and virologic and 
clinical profiles, the natural course of HBV infection and the response to antiviral 
treatment  (IFN +/- NA).  
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3. PATIENTS AND METHODS 
 
 
 
3.1 Patients 
 
We studied 525 consecutive chronic HBV carriers (333 males and 192 females; mean 
age 47.3 years, range 18-86 years), admitted to the Liver Unit of the University Hospital 
of Pisa since 1998 and followed-up prospectively for a median time of 45.2 months 
(range, 12-136.2 months). The study was approved by the Ethical Committee of our 
Hospital and patients gave their written informed consents for participate and for use of 
genetic material in this study. 
Inclusion criteria were: HBsAg positive for at least two years; negative for antibodies 
against hepatitis C virus (HCV), hepatitis D virus, human immunodeficiency virus; 
absence of autoimmune disease and drug or alcohol abuse (> 40 g ethanol/day). 
At the baseline 71 (13.5%) of 525 carriers were HBeAg positive and 454 (86.5%) were 
HBeAg negative, 462 (88%) of them being infected by genotype D, 60 (11.4%) by 
others/mixed genotypes and 3 (0.5%) were  not characterized for the viral genotype.  
To define accurately the phase of infection in each carrier, serum tests were performed 
monthly during the first 12 months of follow-up and every 3 months thereafter. At the end 
of 1-year monthly monitoring, HBV carriers were classified according to their biochemical 
and virological profiles as inactive carriers (IC) if serum HBV-DNA levels were 
persistently ≤ 2000 IU/mL and ALT normal (<40 U/L); as active carriers with low viremia 
(AC1) if HBV-DNA levels were persistently < 20000 IU/mL and  ALT normal;  active 
carriers (AC2) with viremia ≥ 20000 IU/mL independently of ALT values. Quantitative 
HBsAg was tested in all cases at baseline and at the end of follow-up. Transient 
elastography became available in our unit on April 2004 and was performed in all newly 
enrolled patients and in carriers already in follow-up at that time and at least once a year 
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thereafter. Abdominal ultrasound was performed every 12 months in HBV chronic 
carriers and every 6 months in patients with histological diagnosis or US signs of 
cirrhosis. 
Liver biopsies were obtained from 126 (94 males) of the 332 HBeAg negative/anti-HBe 
positive individuals in the AC group; it was not performed in the remaining 79 because of: 
persistently normal ALT and TE values <6 KPa in 42, histological diagnosis of cirrhosis 
already present in 28, signs of cirrhosis at ultrasound in 53, refuse to perform the biopsy 
in 4 patients.  
During follow-up 156 patients (29 HBeAg positive and 127 HBeAg negative) were treated 
with interferon  nucleos(t) ide analogues (NA): 43 were treated with IFN-2a (Roferon; 
Roche SpA) 6-9 MU thrice weekly and 113 with Peg-IFN-2a 180 ug/weekly (Pegasys; 
Roche SpA), 65 of the latter (16 HBeAg positive) received Peg-IFN+NA combination. In 
treated patients liver biochemistry and HBV-DNA and quantitative HBsAg measurements 
were performed at 0-12-24-48 weeks during therapy, at the end of treatment and/or at 
the end of follow-up. Additional samples (week 1-4) were obtained in 42 patients to 
analyze the kinetics of HBV markers  during Peg-IFN therapy.  
A blood sample was collected for IL28B polymorphism (SNP rs 12979860) genotyping at 
baseline or during follow-up. 
 
 
3.2 Serology and Histology 
Serum biochemistry included aspartate-aminotransferase (AST) and alanine-
aminotransferase (ALT), γ-glutamyl transpeptidase, alkaline phosphatase, albumin, 
gammaglobulins, total bilirubin, prothrombin time, α- fetoprotein  were assayed by 
standard procedures. Virological markers such as HBsAg, antibody to hepatitis B surface 
antigen (anti-HBs), antibody to hepatitis B core antigen (anti-HBc), HBeAg and anti-HBe, 
antibody to HCV, antibody to hepatitis D virus and antibody to human immunodeficiency 
virus were detected by commercially available immunoassays (Abbott Laboratories, N 
Chicago, IL).  
IgM anti-HBc levels were determinated by Axsym CORE-M (Abbott Laboratories, N 
Chicago, IL), using 0.200 and 0.100-0.200 index as cut-off and gray zone of chronic 
hepatitis respectively. 
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HBsAg was quantified using the Architect HBsAg assay (Abbott Laboratories; dynamic 
range , 0.05-250.0 IU/mL) after 1:100 dilution. Serum samples with HBsAg levels <0.05 
IU/mL at 1:100 dilution were retested undiluted.  
Serum HBV-DNA levels were determinated by COBAS Amplicor Monitor 2.0 HBV assay 
(Roche Diagnostic System Inc, Mannheim, Germany) with a lower limit of detection of 
200 copies/mL and linearity range from 200 to 20,000 copies/mL (conversion factor 5,6 
copies= 1 IU), until 2005 and thereafter by COBAS TaqMan assay (Roche, sensitivity 12 
IU/ml, dynamic range 6-1.10 X 108 IU/mL.  
HBV genotyping was performed by direct sequencing of the region encoding for the 
small hepatitis B surface protein.  
Genotyping of single nucleotide polymorphisms (SNP rs 12979860) near interleukin 28B 
(IL28B) region was performed in whole blood samples from all subjects, by specific Real 
Time PCR (LightMix, Roche). 
Liver specimens were processed using standard criteria; grading of hepatic inflammation 
and staging of fibrosis were assessed by Ishak score. 
 
 
3.3 Statistical Analysis 
Data were  expressed  as median and range values. Continuous variables were expressed 
as mean ± SD or median and range values. The logarithmic transformation was used for 
quantitative data without normal distribution. Differences between subgroups were analyzed 
using corrected Chi-square test, Mann-Whitney rank sum test or Kruskal-Wallis test as 
appropriate.  Factors independently associated with HBeAg to anti-HBe seroconversion in 
HBe Ag positive patient and HBsAg clearance were identified by using logistic regression 
analysis. 
Statistical analysis was performed by SPSS (version 10.0, SPSS Inc., Chicago, IL, USA).  
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4. RESULTS 
 
 
A total of 525 HBsAg carriers was successfully genotyped at rs 12979860 near IL28B gene. 
Demografic, clinical and virological features of the 525 HBsAg carriers analyzed in the 
study are summarized in table 1. 
Patients were predominantly male of Caucasian origin. All major HBV genotypes were 
present in the study cohort, with the genotype D (88%) the most prevalent. At the 
baseline 71 (13.5%) of 525 carriers were HBeAg positive and 454 (86.5%) were HBe 
negative. According to previous criteria adopted to define the phase of infection, 122 
(26.9%) were classified as inactive carriers, 59 (17.8%) were active carriers with HBV-
DNA levels < 20000 IU/ml and without significant liver disease (AC1), 168 (50.6%) had 
chronic active hepatitis and 105 (31.6%) were cirrhotics. 
Overall, 156 patients were treated with interferon  nucleos(t)ide analogues (NA): 43 were 
treated with IFN-2a (Roferon; Roche SpA) 6-9 MU thrice weekly and 113 with Peg-IFN-
2a 180 ug/weekly (Pegasys; Roche SpA), 65 of the latter received Peg-IFN+NA. 
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Table 1. Patients Characteristics 
                   Characteristics                             Study populations    (n. 525)     
Demographics 
          Mean age (y)                                          47.3 years (range 16-86 years) 
          Male (%)                                                 333 (63.4) 
Follow-up (range) mo.                                      45.2 (12-136.2) 
HBV genotype (%) 
          D                                                             462  (88.0)  
          A                                                               33   (6.2) 
          F                                                                 8   (1.5) 
          C                                                                 6   (1.1) 
          E                                                                 4   (0.7) 
          B                                                                 3   (0.5) 
          Mixed (A/B; A/D; B/C)                                 6   (1.1) 
          Unknown                                                     3   (0.5)  
HBeAg Status (%)                                                 
           HBeAg positive                                        71    (13.5)  
           Anti-HBe positive                                     454  (86.5) 
Phase of infection (%) 
            Inactive carriers (IC)                               122  (26.9) 
            Active carriers                                         332  (73.1) 
Liver disease (%) 
            AC1                                                         59    (17.8)    
            Chronic Hepatitis (CH)                            168   (50.6) 
            Cirrhosis (CI)                                           105   (31.6)          
Treatment (%) 
           Nucleos(t)ide analogues (NA)                  87     
           IFN                                                            91 
           COMBO                                                    65    
 
                    
 
Table 1. Demographic, clinical and virological features of patients analyzed; 
- Inactive carriers (IC): persistently serum HBV-DNA levels < 2000 IU/ml and normal ALT (< 40 U/L); 
- Active carriers without significant liver disease (AC1): HBV-DNA < 20000 IU/ml; 
- Active carriers with Chronic Hepatitis (CH) HBV-DNA ≥ 20000 IU/ml and elevated ALT;  
- Cirrhosis (CI): presence of liver cirrhosis was defined according to histology and liver elastometry 
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4.1 IL28B and baseline features of the patients 
In the overall population the prevalence of IL28B was:  CC 49.7%, CT 40.4% and TT 9.9%.  
The CC allele prevalence did not differ in relation to age, gender (males: 49.5%), 
HBeAg/anti-HBe status (HBeAg pos: CC in 59.2%) and phase of infection (44.3% vs 49.7% 
in inactive and active carriers) (Fig. 6)  
 
 
 
 
 
 
 
-Fig. 6 
 
 
Prevalence of IL28B alleles by phase of the infection
CC         CT       TT
71 454
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40.7%
9.6%
n.s.
122 332
 
 
 
 
Not significant differences were observed concerning the distribution of CC allele in 
genotypes D (CC 52.1%) versus genotypes non-D (CC 53.3%) carriers. 
Median HBV-DNA levels at baseline (BL) were 4.46 Log10 IU/ml in CC, 4.40 Log10 in CT and 
4.34 in TT carriers (n.s). Median HBsAg levels at baseline were 3.34 Log10 IU/ml, 3.18 Log10 
in CT and 3.19 Log10 in TT carriers.   
 
 
4.1.a Distribution according to disease stage  
 
 
We observed not considerable differences in prevalence of IL28B alleles by severity of 
liver disease in 332 HBeAg negative active carriers. The  prevalence of CC allele in 
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HBsAg carriers with HBV-DNA levels persistently < 20000 IU/ml and without significant 
liver disease (AC1) was 54.2 %; in patients with active chronic hepatitis 49.4% and in 
cirrhotics 47.6% (Fig.7) 
 
 
 
 
 
 
 
 
-Fig. 7 
Prevalence of IL28B alleles by severity of liver disease in 332 HBeAg
negative active carriers
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4.1.b Distribution according to histology   
 
Liver biopsies were obtained from 126 of the 332 anti-HBe positive individuals in the AC  
phase. The CC allele prevalence was not statistically different according to the stage of 
fibrosis assessed by Ishak score (Table 2) 
 
Table 2. Staging of liver fibrosis by Ishak score 
 
 C/C C/T T/T Total 
Staging  0 20 
(30.8%) 
10 
(21.3%) 
4 
(28.6%) 
34 
              1 15 10 3 28 
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(23.1%) (21.3%) (21.4%) 
              2 5 
(7.7%) 
8 
(17.0%) 
1 
(7.1%) 
14 
              3 8 
(12.3%) 
6 
(12.8%) 
3 
(21.4%) 
17 
              4 4 
(6.2%) 
4 
(8.5%) 
0 
( .0%) 
8 
              5 9 
(13.8%) 
6 
(12.8%) 
2 
(14.3%) 
17 
              6 4 
(6.2%) 
3 
(6.4%) 
1 
(7.1%) 
8 
Total 65 47 14 126 
 
4.2 IL28B and spontaneous outcome of infection 
 
Of the 22 HBeAg positive untreated patients 8 (36.3%), had a spontaneous HBeAg/anti-
HBeAg seroconversion during a median follow-up of 20 months (range 7-44 m). Not 
significant differences in the IL28B alleles distribution were observed in such 8 patients who 
obtained the seroconversion: 5/14 (35.7%) were CC, 2/6 (33.3%) CT and 1/2 (50.0%) TT 
(Fig. 8) 
Of the 122 inactive carriers 14 (11.5%) spontaneously cleared HBsAg: 4/54 (7.4%) CC, 
8/54 (14.8%) CT and 2/14 (14.3%) TT during a median follow-up of 31.6 months (range 12-
134 m) (Fig. 9). 
 
 
 
- Fig. 8 
 
IL28B alleles prevalence and HBeAg to anti-HBe seroconversion
in 22 HBeAg positive untreated patients
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- Fig. 9 
IL28B alleles prevalence and HBsAg loss in 122 HBeAg negative inactive
carriers
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CC         CT       TT
 
 
 
 
4.3 IL28B and response to IFN treatment 
 
Of the 156 patients who underwent antiviral therapy (IFN +/- NA), 91 were treated with one 
or more courses of Interferon monotherapy, 65 with combination of INF + NA. Among 156 
IFN+/- NA treated pts 29 lost HBsAg: 8 (27.6%) were HBeAg pos (4 CC) and 21 (16.5%) 
HBeAg neg (7 CC). At the multivariate analysis the only independent factor associated with 
HBsAg loss was genotype non D (P=0.001) (Fig. 10). 
In 29 HBeAg positive treated patients (13 with IFN and 16 with IFN+NA), 16 (55.2%) had 
HBeAg to anti-HBe seroconversion  and 8 (18.3%) cleared HBsAg . Not significant 
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differences in the IL28B alleles distribution were observed in HBV carriers that reached 
HBeAg to anti-HBe seroconversion (CC 50%) or HBsAg clearance (CC 25%) during 
antiviral treatment (Fig.12). At  the multivariate analysis  age, gender, HBeAg status, 
disease stage, IL28Bp and treatment were not associated with HBsAg loss (Fig.13). 
Among 127 HBeAg negative patients 78 were treated with interferon alone and 15 of these 
(19.2%) lost HBsAg;  49 HBeAg negative patients were treated with COMBO (IFN + NA)  
and 6/49 (12.3%) cleared HBsAg.  At the multivariate analysis the IL28B polymorphisms  
non one factor (age, gender, genotype and disease stage) was associated with HBsAg lost 
(Fig. 14-15).   
In the soubgroup of 129 genotype D patients treated with IFN +/- NA, 17/129 (13.2%) 
cleared HBsAg (35.3% CC):  4/17 (23.5%) HBeAg positive; 13/17 (76.5%) HBeAg negative. 
At  the multivariate analysis no one factor among age, gender, HBeAg status, disease 
stage, IL28B and treatment was associated with HBsAg clearance (Fig. 11). 
 
 
 
 
- Fig.10 
HBsAg Clearance Univariate
analysis
Multivariate analysis
Yes
(29 pts)
No
(127 pts)
P OR
(95% C.I.)
P
Age Median years
(range)
43.5  
(31-71)
47.0 
(17-69)
N.S.
Gender Males 22 (75.9%) 98 (77.2%) N.S.
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non-D
17 (65.2%)
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13 (12.4%)
0.001
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0.001
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Negative
8 (27.6%)
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21  (16.5%)
106 (83.5%)
N.S.
Disease stage  Cirrhosis 10 (34.5%) 54 (42.5%) N.S.
IL28B                     
CC(CT/TT vs CC)       
CT
TT
11 (37.9%)
15 (51.7%)
3 (10.3%)
73 (57.5%)
44 (34.6%)
10 (5.7%)
0.160
(0.089)
1.446
(0.928-2.255)
0.103
Treatment       IFN   
IFN + NA  
20 (69.0%)
9 (31.0%) 
71 (55.9%)
56 (44.1%)
N.S.
Factors influencing HBsAg clearance in 156 IFN (+/- NA) treated patients
HBsAg clearance in 29 (18%) pts, median f.u. of 45.2 m  (12-136.2)
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- Fig. 11 
HBsAg Clearance Univariate
analysis
Yes
(17 pts)
No
(112 pts)
P
Age Median years
(range)
44  
(31-71)
47.3 
(17-69)
N.S.
Gender Males 13 (76.5%) 84 (75.0%) N.S.
HBeAg Positive
Negative
4 (23.5%)
13 (76.5%)
16 (14.3%)
96 (85.7%)
N.S.
Disease stage  Cirrhosis 5 (29.4%) 50 (44.6%) N.S.
IL28B                     
CC(CT/TT vs CC)        
CT
TT
6 (35.3%)
9 (64.7%)
0 (0.0%)
66 (58.9%)
39 (34.8%)
7  (6.3%)
0.051
Treatment       IFN   
IFN + NA  
11 (64.7%)
6 (35.3%) 
62 (55.4%)
50 (54.3%)
N.S.
Factors influencing HBsAg clearance in 129 Genotype D IFN (+/- NA) treated
patients
HBsAg clearance in 17 (13.2%) pts, median f.u. 43.4 m (12-136.2)
 
 
-Fig. 12 
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Response to antiviral treatment in 29 HBeAg positive patients
16/29 ( 55.2%)  patients had HBeAg to anti-HBe seroconversion
8/29 ( 18.3%) of the patients cleared HBsAg
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N.S.
N.S.
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2/11  (18.2%)
3/11 (27.3%)
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1/5  (20.0%)
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- Fig. 13  
HBsAg Clearance Univariate
analysis
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(8 pts)
No
(21 pts)
P
Age Median years
(range)
43.5 
(35-59)
40.0 
(31-69)
N.S.
Gender Males 7 (87.5%) 20 (95.2%) N.S.
Genotype D 4 (50.0%) 16  (76.2%) N.S.
Disease stage  Cirrhosis 1 (12.5%) 5 (23.8%) N.S.
IL28B                    
CC (CT/TT vs CC)
CT
TT
4 (50.0%)
3 (37.5%)
1 (12.5%)
12 (57.1%)
8 (38.1%)
1  (4.8%)
N.S.
Treatment       IFN   
IFN + NA  
5 (62.5%)
3 (37.5%) 
8 (38.1%)
13 (61.9%)
N.S.
Factors influencing HBsAg clearance in 29 HBeAg positive 
IFN (+/- NA) treated patients
8 (27.6%) patients cleared HBsAg
median follow-up: 44.5 months (12-125) 
 
 
- Fig. 14 
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HBsAg Clearance Univariate
analysis
Yes
(15 pts)
No
(63 pts)
P
Age Median years
(range)
44  
(31-63)
44 
(20-62)
N.S.
Gender Males 12 
(80.0%)
47 
(74.6%)
N.S.
Genotype D
non D
9 (69.2%)
4 (30.8%)
55 (90.2%)
6 (9.8%)
N.S.
Disease stage  
Cirrhosis
7 (46.7%) 25 (39.7%) N.S.
IL28B                    
CC(CT/TT vs CC)
CT
TT
7 (46.7%)
7 (46.7%)
1 (6.7%)
35 (55.6%)
21 (33.5%)
7  (11.1%)
N.S.
Factors influencing HBsAg clearance in 78 HBeAg negative 
IFN treated patients
15/78 (19.2%) patients cleared HBsAg
 
 
 
 
 
 
 
 
 
 
-Fig. 15 
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HBsAg Clearance Univariate
analysis
Multivariate 
analysis
Yes
(6 pts)
No
(43 pts)
P OR
(95% 
C.I.)
P
Age Median years
(range)
42  
(33-71)
54.0 
(17-64)
N.S.
Gender Males 3 (50.0%) 31 (72.1%) N.S.
Genotype D
non D
4 (66.7%)
2 (33.3%)
41 (95.3%)
2 (4.7%)
0.108 N.S.
Disease stage  
Cirrhosis
2 (33.3%) 24 (55.8%) N.S.
IL28B                   
CC(CT/TT vs CC)     
CT
TT
0 (0.0%)
5 (83.3%)
1 (16.7%)
26 (60%)
15 (35%)
2 (4.7%)
0.019 N.S
Factors influencing HBsAg clearance in 49 HBeAg negative 
IFN + NA treated patients
6/49 (12.3%) patients cleared HBsAg
 
4.4 IL28B and kinetics of HBV-DNA and HBsAg decline in 15 HBeAg positive and in  
      27 HBeAg negative patients during Peg-IFN treatment 
 
We analyzed median HBV-DNA and HBsAg decline by IL28B, in 15 HBeAg positive and in 
27 HBeAg negative patients who underwent 48 weeks Peg-IFN mono-therapy. 
After 12 weeks of antiviral therapy mean serum HBV-DNA levels, but not HBsAg serum 
levels, became significantly lower in CC (7) than in CT/TT (7/1) HBeAg positive patients  
(4.94 vs 7.90, P=0.029). The significant faster viral load decline was not associated with 
higher rate of HBeAg seroconversion and HBsAg clearance. No difference in HBV-DNA 
and HBsAg decline was found in HBeAg negative patients (Fig. 16-17-18-19). 
 
 
 
 
 
 
 
 
 
 
 
 
 
-Fig. 16 
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5. DISCUSSION 
 
The outcome of HBV infection is determined by the interplay of the immune response with 
the virus replication, whose ability to persist relies either on the over production of viral 
antigens (HBe and HBs) during the immune-tolerance phase, as well as on the 
development of escape mutants able to reduce the production of the same antigens once  
the host’s immune system activates. For these reasons serologic markers expression of the 
balance between viral replication and immune response (namely HBV-DNA, HBsAg, IgM 
anti-HBc and ALT levels) are commonly used to characterize the disease profile in the 
single case (Brunetto MR et al,  Gastroenterology 2010), and, to some extent, to predict its 
spontaneous evolution or the response to PEGIFN treatment in chronic hepatitis B patients 
(Bonino F, et al Gut 2007).  PEGIFN therapy is recommended as a first line therapy in 
young patients with less advanced liver disease, since sustained responders can ultimately 
achieve HBsAg clearance, which is a proxy of a cure of the infection (Farci P, et al. 
Gastroenterology 2004).  
In spite of the growing knowledge on viral characteristics that influence the outcome of 
antiviral treatment, now including also HBV genotype, it remains unclear which are the 
genetic conditions of the host that play a role in the control of HBV infection.  
Recently, several independent genome-wide association studies (Ge D, Nature 2009) have 
shown that genetic polymorphisms at or near the interleukin 28B gene (IL28B; also known 
as IFN--3), including rs12979860, are associated with higher rates of spontaneous 
clearance after acute infection and sustained virologic response in patients with chronic 
hepatitis C treated with PEG-IFN and ribavirin. The IL28B gene may be implicated in the 
modulation of the innate immune response, thus it may influence also the response to 
PEGIFN in chronic viral hepatitis B. 
The relationship between IFN treatment outcome and IL28B polymorphisms have been 
recently investigated in both HBeAg negative (Lampertico P, Hepatology 2012) and HBeAg 
positive (Sonneveld MJ, Gastroenterology 2012) chronic hepatitis B patients. In the first 
study, Lampertico et al reported the rate of HBsAg clearance with or without anti-HBs 
seroconversion in 101 HBeAg-negative patients (92% genotype D) with compensated 
chronic hepatitis B followed for a median of 11 (1-17) years after median 23 (10-48) months 
of either standard or pegylated PEGIFN alfa therapy. They found a significantly higher 
(p=0.039) rate of HBsAg clearance in CC (29%, 14) than in non-CC genotype (13%, 7) 
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patients. Besides baseline HBV-DNA, ALT levels and duration of IFN, also the IL28B 
genotype CC independently predicted HBsAg clearance (OR 3.9, CI 1.1-13.2, p=0.025), 
therefore the authors suggested that this marker could be used for therapeutic stratification 
of HBeAg-negative genotype D HBV patients. In our study, which enrolled 156 patients 
treated with antiviral therapy (IFN +/- NA), 8 (27.6%) HBeAg positive and 21 (16.5%) 
HBeAg negative lost HBsAg. At the multivariate analysis the only independent factor 
associated with HBsAg clearance was genotype non D (P=0.001) (Fig. 10). In the subgroup 
of 129 genotype D patients treated with IFN +/- NA, 17 (13.2%) cleared HBsAg, with a 
clearance rate that was numerically lower in CC (8.3%) than in non CC (16.4%) patients. At  
the multivariate analysis no factor among age, gender, HBeAg status, disease stage, IL28B 
and treatment was associated with HBsAg clearance (Fig. 11). It should be noted that in our 
cohort the duration of the treatment (median 12 months) and of the subsequent follow up 
(median 44 months) was shorter than in the Lampertico’s study. In addition, the fact that 
31% of the patients who lost HBsAg 44% of those who did not received also NA, suggest 
that our cohort of unselected consecutive patients have a more difficult to treat liver 
disease. This finding could explain the lower overall HBsAg clearance rate observed. In 
addition the long term treatment with NA before and after IFN could impair some antiviral 
immune responses which are somehow related to the IL28B polymorphism. It is interesting 
to note that in the small HBeAg positive cohort, our viral kinetics findings are conceivable 
with the increased probability of HBeAg/anti-HBe seroconversion during long-term follow-up 
in CC patients reported by Sonneveld. In fact,  during peg-IFN mono-therapy week 12 HBV-
DNA, but not HBsAg levels, became significantly lower in CC (7) than in non CC (8) HBeAg 
positive patients  (4.94 vs 7.90, P=0.029). On the contrary, such a difference was not found 
in HBeAg negative patients (fig. 8-9). This evidence support the hypothesis that in HBeAg 
positive patients, where the high replication activity needs to be blocked to achieve the 
control of the infection, the IL28B polymorphisms may identify patients who have different 
degree of sensitivity to the IFN induced direct antiviral effects driven by innate immunity 
response. Such mechanisms has already been proven to play a major role in the setting of 
HCV infection (Naggie et al, Hepatology 2012; vol 56, no 2:444-454). By contrast, in HBeAg 
negative carriers with long lasting infection, the role of the innate immunity responses are 
considered to be less important for the achievement of a stable immune control. If this is the 
case, the finding of this study, namely a similar CC allele prevalence in Inactive and in 
Active Carriers, would be in line with the view that the mechanisms of HBV control and 
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HBsAg clearance are more likely governed by adaptive immunity and less related to  
genetic polymorphisms influencing the sensitivity to IFN. 
 
 
6. CONCLUSIONS 
 
 
In our cohort of chronic HBV carriers the IL28B CC allele does not correlate with the phase 
of HBV infection, with the baseline HBsAg and HBV-DNA serum levels. 
Favourable outcomes of chronic HBV infection, defined as spontaneous HBeAg to anti-HBe 
seroconversion in HBeAg positive patients and HBsAg clearance in anti-HBe positive 
inactive carriers were not influenced by IL28B polymorphism. 
HBsAg clearance after IFN +/- NA was not influenced by IL28B polymorphism. 
During the first 12 weeks of Peg-IFN therapy, viral load decline was higher in CC genotype 
HBeAg positive patients. However, the higher viral load decline was not associated with 
higher HBeAg/anti-HBe seroconversion rate. 
Overall these findings underline major differences in the mechanisms of natural and therapy 
induced control of HBV and HCV infections. 
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